Trust Isn't Earned. It's Engineered.
Here is the assumption most veterinary and health technology founders are working from.
If they show up consistently, build their credentials carefully, and demonstrate results clearly enough, trust will follow. It will accumulate. The relationship will deepen. The buyer will eventually believe.
This is not entirely wrong. Consistency matters. Credentials matter. Results matter.
But the assumption is incomplete in a way that has specific, expensive consequences.
Trust does not accumulate evenly. It forms at specific moments. It breaks at others. And in a market where buyers are professionally trained to be skeptical of technology promises, a strategy built around the hope that trust will accumulate is not a trust strategy. It is a waiting strategy.
The difference between those two things is the difference between commercial momentum and another quarter of quiet hesitation.
I work with founders across veterinary and health technology markets who hold this assumption. The gap between what they expect trust accumulation to do and what it actually produces is where most of my Q3 conversations start.
The Credentials Trap
Walk into most veterinary markets with a new technology and you will be carrying credentials. Peer-reviewed data. A successful pilot. Endorsements from clinicians with names buyers recognize. These are real assets and they should exist.
Here is what I see happen, consistently, when credentials become the primary trust strategy in a conservative clinical market.
You add more of them. More proof points. More case studies. More validation from more sources. The reasoning is clear: if the buyer is hesitating, they must need more evidence. So you provide more evidence.
The hesitation does not resolve. And you cannot understand why, because the evidence is genuinely strong.
This is the credentials trap. More proof stops producing more trust, and the strategy of adding proof points begins to feel like the only lever available.
Credentials establish a floor. They tell a buyer you are worth considering. They do not tell a buyer you are worth trusting. In a market where every serious vendor has credentials, the floor has never been higher and has never mattered less to the actual trust decision.
That is not a proof problem. That is a design problem.
Where Trust Actually Forms
Trust does not form in the data room. It forms in the moments between the data.
In veterinary and health technology markets, the moments where trust either begins or breaks are almost never the ones companies design for. They are the moments companies assume are administrative. Routine. Not worth engineering.
I have watched companies design carefully for the formal touchpoints and treat the moments between them as logistics. That gap is where trust quietly erodes.
The follow-up after a first conversation that arrives three days later than expected. Not because the team dropped the ball, but because no one thought to design that handoff as a trust moment.
The demo that goes well, followed by a silence that lasts longer than the buyer expected. The champion who wanted to carry the story internally but did not have the tools to do it. The onboarding that replaced the implementation manager the buyer trusted with someone who had to start from scratch.
None of these are dramatic failures. None of them announce themselves as the moment trust broke.
They are small. They compound. And months later, when the deal has gone quiet, no one can point to the specific moment where the relationship lost momentum. Because trust does not break loudly. It erodes quietly, in the gaps between the moments a company designs for.
The Three Moments That Matter Most
Not all trust moments are equal. In conservative clinical markets, there are three where the stakes are highest and the design attention is usually lowest.
The first is the transition from promise to proof. The gap between what a company says in a sales conversation and what the buyer experiences in the first thirty to sixty days of actual use. Clinical buyers do not extend credit generously across this gap. That caution is not abstract. Veterinary services have risen 51.2% since 2019, running at nearly double the pace of overall inflation, which means the practices you’re selling into are already operating with a thinner margin for error than they had a few years ago. What they experience in the first real encounter with a product in their workflow either confirms the promise or begins to erode it. There is very little middle ground.
The second is the internal champion moment. In veterinary and health technology purchases, the person who evaluates a product is almost never the person who makes the final decision alone. They have to carry the story: to a practice owner with different priorities, to an administrator focused on cost, to a clinical team that has its own version of the problem. A buyer who believes in the product personally but cannot carry it internally will not close. The trust the company built through evidence does not transfer automatically to the people who were not in the room.
The third is the post-decision window. What a buyer experiences immediately after they commit. Before implementation begins. Before results are visible. In the window where the cognitive weight of a difficult decision is highest and the reassurance that they chose well is most valuable. This is the moment most companies treat as logistics. It is one of the highest-leverage trust moments in the entire relationship.
The Hope-It-Accumulates Approach vs. The Deliberate Trust System
Most trust strategies in this market are not really strategies. They are assumptions about accumulation.
Show up consistently and trust will form. Add more proof and the hesitation will resolve. Build credentials and the relationship will deepen. Produce good work and the reputation will spread.
These things are true over a long time horizon in a forgiving market. They are not sufficient in a conservative clinical market where buyers are evaluating risk carefully, adoption cycles are measured in quarters, and the cost of a wrong decision lands on actual animals and actual clinicians.
A deliberate trust system starts from a different question: in this market, with this buyer, at this stage of the relationship, what does trust actually require?
Not what evidence we have. What this specific person needs to feel that this company, this team, this implementation, this relationship is worth the risk they are being asked to take.
That question has a different answer for a practice owner evaluating a workflow technology for her three-doctor practice than it does for an operations leader assessing the same technology for a corporate group with fourteen locations. A different answer at the awareness stage than at the evaluation stage. A different answer for a buyer who has been burned by a previous vendor than for one evaluating the category for the first time.
Before You Plan Anything Else This Week
Pick one deal from this quarter that stalled after a strong meeting. Not the ones that never had a chance. One that felt right and then went quiet.
Find the exact moment your team stopped treating the next touchpoint as a trust moment and started treating it as logistics. The follow-up that got deprioritized. The materials your champion didn’t have on hand. The first thirty days nobody checked on.
Name that moment before you read anything else this week. Not the theory of where it broke. The specific day.
If you can’t name the day for even one deal, that’s the finding worth sitting with. It means nobody on your team is watching the moments this piece is about. They’re watching the meetings instead.
That is the starting point for a deliberate trust system. Not a bigger deck. Not another endorsement. The moment you stopped designing and started assuming.
Trust is not what you earn through effort over time. It is what you engineer for the moments that matter most.
This quarter at Thavma Insights, we are building the full argument for trust as an engineered system, moving through where trust breaks, how the Modern 4Ps function as a trust-building system, and how to run a Trust Gap Audit on your own business.
The Trust Gap eGuide operationalizes all of it into a system you can run. It arrives this August.
About Thavma Consulting
Thavma Consulting works with founders and commercial leaders building complex veterinary and health technology solutions. We help teams build the go-to-market systems that connect strategy to the decisions that actually close deals and drive adoption.